EPAM Life Sciences Awarded Grand Prize at Bio-IT World Best Practices Competition 2015

EPAM Life Sciences Awarded Grand Prize at Bio-IT World Best Practices Competition 2015

AccelEpi, an EPAM and UCB project, won the grand prize at the 11thannual Bio-IT World Best Practices Awards, a competition celebrating technology innovations in the life sciences industry.

Newtown, PA — May 27, 2015 — EPAM Systems (NYSE:EPAM), a leading provider of software product development services, today announced that AccelEpi, a joint EPAM-UCB project, won the Bio-IT World Best Practices Award for Research and Drug Discovery. AccelEpi – Automated Accelerometric Detection of Epileptic Seizures in Rodents – is the first truly transformational technology platform that allows for a non-invasive, routine use of rodent models for research in drug discovery studies aiming at disease modification in epilepsy.

According to Dr. Rafal Kaminski, Head of Epilepsy at UCB,

“The exceptional collaboration between UCB and EPAM Life Sciences resulted in an innovative discovery platform known as AccelEpi that accelerates the detection process of epileptic seizures in rodent experiments”.

Dr. Kaminski explained that,

“With such an innovative system, we may not only test drugs more quickly, but for the first time employ true disease models in antiepileptic drug discovery projects, which enables development of curative or disease-modifying therapies for patients with epilepsy”.

In fact, as mentioned by Xavier Van Damme, the project leader,

“AccelEpi is an excellent example of how multidisciplinary research involving signal analysis, software and IT infrastructure specialists working together with disease experts enables innovative drug discovery”.

“AccelEpi allows UCB to transition from measuring its drug candidates by their ability to fight induced seizures to proactively monitoring how those drug candidates reduce the rate of natural seizures in more true-to-life conditions,”

said Richard Golob, Head of EPAM Life Sciences.

“The platform is scaled to monitor up to 64 experimental animals in parallel, which enables running dose-response drug studies in real-time and significantly decreases the cost of experiments”.

Every year, Bio-IT World focuses attention on the critical role of IT in modern biomedical research and highlights platforms and strategies that can be shared across the industry to improve the quality, pace, and reach of science.

“We are delighted once again to see such exceptional projects entered in this year’s competition,”

said Allison Proffitt, editor of Bio-IT World.

“The use of information technology has the potential to reinvigorate the life sciences in so many ways, and the winners of this year’s awards have shown creativity and initiative in applying these tools to problems large and small”.

About EPAM Systems

Established in 1993, EPAM Systems, Inc. (NYSE: EPAM) is recognized as a leader in software product development by independent research agencies. Headquartered in the United States, EPAM serves clients worldwide utilizing its award-winning global delivery platform and its locations in 19 countries across North America, Europe, Asia and Australia. EPAM was ranked #6 in 2013 America’s 25 Fastest-Growing Tech Companies and #3 in 2014 America’s Best Small Companies lists by Forbes Magazine.

Forward-Looking Statements

This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Source: EPAM

    Popular posts

    Related posts